The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease

AIMS: The sodium‐glucose co‐transporter 2 inhibitor empagliflozin reduced the total burden of cardiovascular, mortality, and all‐cause hospitalization events, including first and recurrent events, in EMPA‐REG OUTCOME participants with type 2 diabetes (T2D) and established atherosclerotic cardiovascu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaku, Kohei, Wanner, Christoph, Anker, Stefan D., Pocock, Stuart, Yasui, Atsutaka, Mattheus, Michaela, Lund, Søren S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305124/
https://www.ncbi.nlm.nih.gov/pubmed/34908223
http://dx.doi.org/10.1111/dom.14626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305124/
https://www.ncbi.nlm.nih.gov/pubmed/34908223
http://dx.doi.org/10.1111/dom.14626

Ejemplares similares